Achillion Pharmaceuticals (ACHN) Shares are Down -4.92%

Achillion Pharmaceuticals (ACHN) : During the past 4 weeks, traders have been relatively bearish on Achillion Pharmaceuticals (ACHN), hence the stock is down -10.85% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.4% relative to the S&P 500. The 4-week change in the price of the stock is -10.97% and the stock has fallen -4.92% in the past 1 week.

The stock has recorded a 20-day Moving Average of 7.19% and the 50-Day Moving Average is 5.36%.The 200 Day SMA reached 3.59%. Achillion Pharmaceuticals, Inc. has dropped 17.65% during the last 3-month period . Year-to-Date the stock performance stands at -24.75%.


Achillion Pharmaceuticals (NASDAQ:ACHN): The stock opened in the green at $8.28 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $8.31 and a low of $8.09 for the day. The stock did not find buyers even at the lows and closed at $8.12 recording a loss of -1.34%. 758,927 shares exchanged hands during the trading day. The stock had closed at $8.23 in the previous days trading.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.